Achieve Life Sciences Inc.

Achieve Life Sciences Inc. is a biotechnology company focused on the research and development of therapies to aid in addiction cessation, with a particular emphasis on smoking cessation products. Its primary focus is the development of cytisinicline, a plant-based alkaloid that acts as a partial agonist for nicotinic acetylcholine receptors, providing a novel approach to helping individuals quit smoking by reducing nicotine addiction withdrawal symptoms. Operating within the healthcare and pharmaceutical sectors, Achieve Life Sciences plays a crucial role in developing innovative health solutions in response to growing concerns over tobacco-related diseases. By advancing clinical trials and regulatory evaluations, the company aims to address significant public health challenges and meet the demand for more effective cessation therapies. With headquarters in the United States, Achieve Life Sciences contributes to a vital aspect of the pharmaceutical industry dedicated to improving public health outcomes and providing an integrated scientific approach to addiction management.